Company intelligence / Profile preview

aptaTargets

Madrid, Madrid, Spain

Ownership: Private
Development stage: Phase 2

Overview

Successfully completed First-in-Human clinical trial in healthy volunteers (Phase I, NCT04742062) in 2019-2020. Phase Ib portion of a Phase Ib/IIa trial in acute ischemic stroke patients (APRIL study, NCT04734548) was completed in June 2021. Currently advancing to clinical Proof-of-Concept in patients.

Therapeutic areas: CardiovascularNeurology
Modalities: Aptamers (single-stranded DNA molecules)
Industry: Biotech

Drug pipeline

1 asset

aptoll

Partnerships

Complutense UniversityRamon y Cajal Hospital

Beyond the preview

Go deeper on aptaTargets.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aptaTargets.

Explore the full profile